Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve | NEJM
Anticoagulation for Mechanical Heart Valves | Arteriosclerosis, Thrombosis, and Vascular Biology
Surgery | Thrombosis Adviser
Clinical Bioprosthetic Heart Valve Thrombosis After Transcatheter Aortic Valve Replacement: Incidence, Characteristics, and Treatment Outcomes | JACC: Cardiovascular Interventions
Characteristics of the optimal candidate for mechanical heart valve... | Download Scientific Diagram
Prosthetic Heart Valve Thrombosis | Journal of the American College of Cardiology
2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation - Chao - 2021 - Journal of Arrhythmia - Wiley Online Library
RIVER Trial Presented at #AHA20 / Twitter
Triple Antithrombotic Therapy: Risky but Sometimes Necessary | Revista Española de Cardiología
Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model | Arteriosclerosis, Thrombosis, and Vascular Biology
Effectiveness and Safety of Off-label Dosing of Non–vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients | Scientific Reports
![PDF] Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b848b4c36977bfee20ba4b3ed5bd220554206359/3-Figure1-1.png "PDF] Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study | Semantic Scholar")
PDF] Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study | Semantic Scholar
Rivaroxaban is Comparable to Warfarin for Bioprosthetic Mitral Valves and AF | DAIC
Optimal Anticoagulation After Tissue Aortic and Mitral Valve Replacement - Seminars in Thoracic and Cardiovascular Surgery
Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model | Arteriosclerosis, Thrombosis, and Vascular Biology
Valvular heart disease subanalyses of direct oral anticoagulant atrial... | Download Table
AHA 2020: Rivaroxaban comparable to warfarin for patients with atrial fibrillation and prosthetic valves - Cardiovascular News
Comparison of phase III studies of apixaban, rivaroxaban, and... | Download Table
Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve–Induced Thrombin Generation - The Annals of Thoracic Surgery
Antithrombotic Therapy in Patients With Valvular Heart Disease
Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study. - Abstract - Europe PMC
Rivaroxaban Versus Warfarin in Patients with Mechanical Heart Valves: Open-Label, Proof-of-Concept trial—The RIWA study | SpringerLink
Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve–Induced Thrombin Generation - The Annals of Thoracic Surgery
A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial - ScienceDirect
